GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lantern Pharma Inc (NAS:LTRN) » Definitions » Price-to-Owner-Earnings

Lantern Pharma (Lantern Pharma) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lantern Pharma Price-to-Owner-Earnings?

As of today (2024-06-08), Lantern Pharma's share price is $5.58. Lantern Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Lantern Pharma's Price-to-Owner-Earnings or its related term are showing as below:


LTRN's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.745
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), Lantern Pharma's share price is $5.58. Lantern Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.63. Therefore, Lantern Pharma's PE Ratio for today is At Loss.

As of today (2024-06-08), Lantern Pharma's share price is $5.58. Lantern Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.63. Therefore, Lantern Pharma's PE Ratio without NRI for today is At Loss.


Lantern Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Lantern Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantern Pharma Price-to-Owner-Earnings Chart

Lantern Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Lantern Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lantern Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Lantern Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lantern Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lantern Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lantern Pharma's Price-to-Owner-Earnings falls into.



Lantern Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lantern Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=5.58/-1.36
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lantern Pharma  (NAS:LTRN) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lantern Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lantern Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lantern Pharma (Lantern Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Executives
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund I, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund I Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Cavu Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Advisors Gp, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Cavu Advisors, Llc 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bp Directors, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Maria-luisa Maccecchini director 1223 FOXGLOVE LANE, WEST CHESTER PA 19380

Lantern Pharma (Lantern Pharma) Headlines

From GuruFocus